This article was originally published in The Gray Sheet
Executive SummarySigns a letter of intent to sell $2 mil. of its unregistered common stock to International Capital Partners, a Stamford, Connecticut- based firm that specializes in advising smaller-growth companies. Biopool plans to use proceeds from the financing "to pay down existing debt, for capital equipment and expenditures, to increase research and development, and to promote marketing efforts." The Ventura, California-based producer of test kits to assess and diagnose vascular system disorders expects to complete the financing by April 30.
You may also be interested in...
CMR Surgical CEO Martin Frost is making way for a new boss to lead the surgical robotics company. Per Vegard Nerseth is set to join CMR Surgical in January 2020 as the company gears up for its most ambitious year yet.
While the BCMA-targeting CAR-T competition is grabbing attention, bluebird has good news in sickle cell therapy.
AstraZeneca’s Lynparza can now be used on the Scottish National Health Service for newly diagnosed advanced ovarian cancer.